Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 7569 - 7576 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCN6217 | Cinnamic acid |
|
Cinnamic acid, a naturally occurring aromatic fatty acid of low toxicity, has anti-diabetic ,
anticancer and antioxidant activities. It is a cell differentiation inducer and protein isoprenylation inhibitor, shows a significant radio-protective effect by reducing the DNA damage induced by X-rays. Cinnamic acid inhibited feeding by detritivores, this inhibition occurs at concentrations found in nature and may be a major factor controlling the rate of decay of organic matter. It inhibited mushroom tyrosinase activity in reversiblywith the IC 50 value of 2.10 mM. |
|
| BCN6219 | Sweroside |
|
Sweroside possesses wound healing, cytoprotective, skin-whitening , anti-osteoporotic
, and hepatoprotective effect. It can inhibit potent melanogenesis in melan-a cells at 300uM without cytotoxicity, also decreases tyrosinase, tyrosinase-related protein-1 (TRP-1) and TRP-2 protein production in melan a cells. It also shows insulin-mimicking effects on the regulation of Pck1 expression. |
|
| BCN6222 | Ergosterol peroxide glucoside |
|
1. Ergosterol peroxide exhibits inhibitory effects on human breast adenocarcinoma MCF-7 cells, it inhibits the growth of MCF-7 cells by inducing cell apoptosis.
2. Ergosterol peroxide exhibits hACAT-1 and Lp-PLA2 inhibitory effects, with inhibitory values of 51.6 +/- 0.9 and 51.7 +/- 1.2%, at a treatment concentration of 0.23 mM; suggests that it could as an anti-atherosclerosis agent. 3. Ergosterol peroxide shows very strong anticomplementary activity on the classical pathway, the IC(50) values being 5.0 muM. 4. Ergosterol peroxide can suppress inflammatory responses in RAW264.7 macrophages and growth of HT29 colon adenocarcinoma cells, it appears to suppress cell growth and STAT1 mediated inflammatory responses by altering the redox state in HT29 cells. 5. Ergosterol peroxide has anti-melanogenic activity. 6. Ergosterol peroxide has amoebicidal activity (IC50 =4.23nM), it produces a strong cytotoxic effect against amoebic growth. 7. Ergosterol peroxide has osteoclastogenesis inhibitory effect, it shows an inhibitory effect in a dose-dependent manner and an inhibition rate of up to 62% with low cytotoxicity, even at a concentration as low as 1.0 microg/mL. 8. Ergosterol peroxide has antibacterial activity against Mycobacterium tuberculosis and has antiviral action. 9. Ergosterol peroxide has anti-oxdiant activity. |
|
| BCN6223 | Methyl chanofruticosinate |
|
1. Methyl chanofruticosinate has weak anti-HIV-1 activity.
|
|
| BCN6224 | 12-Hydroxyjasmonic acid |
|
1. 12-Hydroxyjasmonic acid glucoside is a COI1-JAZ-independent activator of leaf-closing movement in samanea saman.
|
|
| BCN6225 | Shizukaol C |
|
1. Shizukaol C shows anti-HIV-1 replication activities in both wild-type HIV-1 and two NNRTIs-resistant strains.
2. Shizukaol C has significant cytotoxicities against C8166 cells. |
|
| BCN6226 | Shizukaol D |
|
1. Shizukaol D exerts a growth inhibition effect on liver cancer cells in a dose- and time-dependent manner by modulating wnt signalling pathway.
2. Shizukaol D induces mitochondrial dysfunction by depolarizing the mitochondrial membrane and suppressing energy production, which may result in AMPK activation, suggests that shizukaol D may be used to treat metabolic syndrome. |
|
| BCN6228 | Glyasperin A |
|
1. Glyasperin A has cytotoxic properties against P-388 cells, its IC50 values being 6.0 microM.
|
|
